Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT). [More]
Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

The nervous system is built to last a lifetime, but diverse diseases or environmental insults can overpower the capacity of neurons to maintain function or to repair after trauma. A team led by Dr. Hernán López-Schier, head of the Research Unit Sensory Biology and Organogenesis at Helmholtz Zentrum München, now succeeded in promoting the repair of an injured neural circuit in zebrafish. [More]
Gestational diabetes mellitus screening provides more health benefits to pregnant women

Gestational diabetes mellitus screening provides more health benefits to pregnant women

A local research study conducted by KK Women's and Children's Hospital and Duke-NUS Graduate Medical School has found that pregnant patients benefit most from gestational diabetes mellitus (GDM) screening as it allows for timely interventions and brings about health benefits that far outweigh the cost. [More]
Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA. [More]
Diabetes prevention begins in the womb

Diabetes prevention begins in the womb

60 million people worldwide are living with diabetes mellitus, and one in ten people over the age of 25 will develop the condition (type 2) at some stage in their lives. Globally, around 3.4 million people die from diabetes and its consequences every year. "Every six seconds, somebody somewhere in the world dies from diabetes", says Alexandra Kautzky-Willer from the Department of Endocrinology and Metabolism at the MedUni Vienna's University Department of Internal Medicine III. [More]
New funding for Centenary's life saving research

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today. [More]
Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco. [More]
Understanding molecular mechanisms underlying human aging

Understanding molecular mechanisms underlying human aging

Researchers have found differences between normal and pathologic peptidomic changes that may lead to an improved understanding of molecular mechanisms underlying aging. Proteome analysis in combination with therapy may influence pathologic aging. [More]
NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS Blood and Transplant will start producing stem cells for groundbreaking treatment aimed at combating one of the most serious health problems facing the NHS, diabetic kidney disease. [More]
Women with Type 2 diabetes face barrier to physical activity

Women with Type 2 diabetes face barrier to physical activity

Women with Type 2 diabetes experience a barrier to physical activity that threatens to make them more sedentary and cause their health to worsen, according to a new study by Amy Huebschmann, MD, MS of the University of Colorado Anschutz Medical Campus. [More]
Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus. [More]
Bariatric surgery results in substantial weight loss in overweight children with Prader-Willi syndrome

Bariatric surgery results in substantial weight loss in overweight children with Prader-Willi syndrome

Obesity is a leading cause of complications and death in children suffering from Prader-Willi syndrome (PWS), yet there are few effective treatment options for these patients. In a new study published in Surgery for Obesity and Related Disease researchers found that bariatric surgery, specifically laparoscopic sleeve gastrectomy (LSG), resulted in substantial weight loss with no apparent adverse effect on growth in a small group of severely overweight patients with PWS. [More]
Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours. [More]
Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology. [More]
Prenatal exposure to historical Ukraine Famine increases risk for Type 2 diabetes

Prenatal exposure to historical Ukraine Famine increases risk for Type 2 diabetes

Men and women exposed in early gestation to the man-made Ukrainian Famine of 1932-33 in regions with extreme food shortages were 1.5 times more likely to be diagnosed with Type 2 diabetes in adulthood. [More]
Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA. [More]
Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP]. [More]
Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix Corp. is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL." [More]
ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research. [More]
Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels. [More]
Advertisement
Advertisement